| BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours | Bonn, Ulm | Phase I / Phase II | rekrutiert |
| Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination Wit | Dresden, Erlangen, Essen | Phase I / Phase II | rekrutiert |
| ColoCare Study - Colorectal Cancer Cohort | Heidelberg | — | rekrutiert |
| ColoReg: A Register for Gastrointestinal Endoscopy Reports and Examination Videos | Stuttgart, Würzburg | — | rekrutiert |
| Comparison of the Physical Activity in Cancer Patients Assessed by Questionnaire and Motion Trac | Greifswald | — | rekrutiert |
| Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer | München, Wuppertal | — | rekrutiert |
| FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer | Tübingen | Phase I | rekrutiert |
| Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor | Amberg, Berlin, Düsseldorf | Phase II | rekrutiert |
| MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors | Berlin, Dresden, Essen | Phase I | rekrutiert |
| Multicentre Study for Data Collection, Development, and Evaluation of Novel CRC Screening and Di | Lübeck, Mainz-GE | — | rekrutiert |
| Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors | Essen | Phase I | rekrutiert |
| Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cance | Köln, Essen, München | Phase I | rekrutiert |
| Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - POR | Amberg, Bad Saarow, Bayreuth | Phase III | rekrutiert |
| Predicting Cancer Risk With Digital and Molecular Markers | Please Refer to Project Homepage For Details (see Link Below) | ohne Phasenangabe | rekrutiert |
| START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | Frankfurt am Main, Heidelberg, Tübingen | Phase I | rekrutiert |
| Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Adv | Berlin, Essen, Hannover | Phase II | rekrutiert |
| Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants W | Köln, Esslingen am Neckar, Moers | Phase I / Phase II | rekrutiert |
| Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positiv | Berlin, Frankfurt am Main | Phase II | rekrutiert |